Subscribe To
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering therapy TOKYO and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) — Eisai Co., […] The post Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzhei...
Read More
Posted: Jul 19 2023, 23:30
Author Name: forextv
Views: 080941